- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07560293
3D-EIT for Diagnosis and Monitoring of Pulmonary Embolism (TIDE-PE)
Prospective Validation of Three-Dimensional Electrical Impedance Tomography for the Diagnosis, Risk Stratification, and Longitudinal Monitoring of Pulmonary Embolism
Studieoversikt
Status
Detaljert beskrivelse
Pulmonary embolism (PE) is a major cause of morbidity and mortality. Computed tomography pulmonary angiography (CTPA) is the current reference standard for PE diagnosis, but it is limited by radiation exposure, contrast administration, and poor suitability for bedside or repeated dynamic assessment. Three-dimensional electrical impedance tomography (3D-EIT) is a non-invasive, radiation-free imaging technique that enables bedside evaluation of regional lung ventilation and perfusion.
The objective of this study is to validate the clinical utility of 3D-EIT for the diagnosis, risk stratification, and longitudinal monitoring of PE. The study will focus on EIT-derived ventilation-perfusion parameters, including the Matching Index (MI), Dead Space Index (DI), and Shunt Index (SI).
This is a prospective, single-center, observational case-control study conducted at Beijing Tsinghua Changgung Hospital. Two cohorts will be enrolled:
- A control cohort without PE or VTE, recruited from patients scheduled for saphenous vein radiofrequency ablation for varicose veins who meet predefined screening criteria.
- A PE cohort including patients with a first episode of PE confirmed by CTPA. Participants in the control cohort will undergo one 3D-EIT examination to establish reference ranges for MI, DI, and SI. Participants in the PE cohort will undergo 3D-EIT within 24 hours after diagnostic CTPA. Repeated EIT examinations will be performed after thrombolytic therapy when applicable, at hospital discharge, and at 1-month follow-up to evaluate dynamic changes over time.
The primary objective is to assess the diagnostic performance of MI and DI for identifying PE using CTPA as the reference standard. Secondary objectives include evaluating the association of EIT-derived indices with PE severity, CTPA-based obstruction burden, risk stratification category, and temporal changes following treatment.
Statistical analyses will include estimation of reference ranges in the control cohort, receiver operating characteristic (ROC) analysis for diagnostic performance, correlation analyses between EIT and CTPA-derived parameters, and longitudinal analyses of repeated EIT measurements in the PE cohort.
Studietype
Registrering (Antatt)
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Age 18 years or older
- Body mass index (BMI) less than 50 kg/m²
- Able to provide written informed consent
- first episode of pulmonary embolism confirmed by CT pulmonary angiography (CTPA), with or without CT venography (CTV)
Exclusion Criteria:
- Previous diagnosis of pulmonary embolism
- Pregnancy
- Thoracic deformity or chest wall abnormality preventing proper placement of the EIT electrode belt
- Contraindications to EIT use, including implantable cardioverter-defibrillator, pacemaker, implanted pumps, or chest wounds limiting electrode placement
- Concurrent participation in another interventional clinical study Hemodynamic instability requiring emergency intervention that precludes completion of the EIT examination (PE cohort only)
- Any other condition judged by the investigator to make the participant unsuitable for study participation
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Diagnostic Accuracy of EIT-derived Dead Space Index (DI) for Pulmonary Embolism
Tidsramme: Baseline (within 24 hours after CTPA for the PE cohort and at enrollment for the control cohort)
|
Sensitivity, specificity, and area under the receiver operating characteristic curve (AUC) of the Dead Space Index (DI) measured by 3D-EIT for diagnosing pulmonary embolism, using CT pulmonary angiography (CTPA) as the reference standard.
|
Baseline (within 24 hours after CTPA for the PE cohort and at enrollment for the control cohort)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Diagnostic Accuracy of EIT-derived Matching Index (MI) for Pulmonary Embolism
Tidsramme: Baseline (within 24 hours after CTPA for the PE cohort and at enrollment for the control cohort)
|
Sensitivity, specificity, and area under the receiver operating characteristic curve (AUC) of the Matching Index (MI) measured by 3D-EIT for diagnosing pulmonary embolism, using CT pulmonary angiography (CTPA) as the reference standard.
|
Baseline (within 24 hours after CTPA for the PE cohort and at enrollment for the control cohort)
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 3D-EIT for PE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Venøs tromboembolisme (VTE)
-
Feeltect LimitedParkview HealthHar ikke rekruttert ennåVenous Leg -magesår (Vlus)Forente stater
-
Alexion Pharmaceuticals, Inc.Portola Pharmaceuticals, LLC (a wholly owned subsidiary of Alexion Pharmaceuticals)AvsluttetVTE-profylakseForente stater, Storbritannia, Den russiske føderasjonen, Ukraina
-
Janssen Research & Development, LLCFullførtVTE-profylakse med antikoagulasjon etter total kneprotesekirurgiBelgia, Italia, Malaysia, Latvia, Spania, Tyrkia, Bulgaria, Forente stater, Litauen, Den russiske føderasjonen, Ukraina, Japan, Argentina, Brasil, Canada, Polen
-
Thomas Jefferson UniversityRekrutteringAmming | Postpartum | Innsamling av morsmelk | Rivaroksaban | VTE-profylakse | VTE (venøs tromboembolisme)Forente stater
-
Chinese Academy of Medical Sciences, Fuwai HospitalUkjent
-
StimLabsHar ikke rekruttert ennåBensår | Venøse bensår | Bensår Venøs | Venøst ben | Venous Leg -magesår (Vlus)
-
Infanta Leonor University HospitalFundación para la Investigación e Innovación Biomédica del Hospital Universitario...RekrutteringVenøs tromboembolisme (VTE) | Okkult kreftSpania
-
McMaster UniversityCanadian Venous Thromboembolism Clinical Trials and Outcomes Research... og andre samarbeidspartnereHar ikke rekruttert ennåVenøs tromboembolisme (VTE) | Hoftebruddkirurgi | Kardiovaskulær forebyggingCanada, Italia
-
Regeneron PharmaceuticalsRekrutteringVenøs tromboembolisme (VTE)Forente stater, Japan, Litauen, Ungarn, Latvia, Polen, Bulgaria, Romania
-
University Hospital, BrestRekrutteringVenøs tromboembolisme (VTE)Frankrike